Maryvonne Hiance is Chairman of France Biotech, the Association of French Biotechnology and Life Sciences companies. She’s Vice Chairman of the Board of OSE Immunotherapeutics, a company dedicated to the development of innovative immunotherapies in the fields of immuno-oncology, autoimmune diseases and transplantation. Over a 20-year period, she held the position of General Manager at innovative biotechnology companies including SangStat Atlantic, DrugAbuse Sciences and TcLand. Ms. Hiance also founded Strategic Ventures, a consulting company, and Effimune, a biotechnology company specialized in immune regulation.
Ms. Hiance holds an Engineering Degree from the « Ecole Polytechnique Feminine », Paris, and a Nuclear Engineering Degree from the « Institut des Sciences et Techniques », Grenoble.